Contribution of the BioFire® FilmArray® Meningitis/Encephalitis Panel:

Assessing Antimicrobial Duration and Length of Stay

Abstract

Introduction. Traditional evaluation of meningitis includes cerebrospinal
fluid (CSF) culture and gram stain to pinpoint specific causal
organisms. The BioFire® FilmArray® Meningitis/Encephalitis (ME)
Panel has been implemented as a more timely evaluation method.
This study sought to assess if the BioFire® ME Panel was associated
with a decreased length of stay or decreased antimicrobial duration
when used in the diagnosis of meningitis or encephalitis.
Methods.xA case, historical-control, chart review was performed on
patients admitted to a regional medical center with CSF pleocytosis
during Cohort 1 (the year prior to BioFire® ME Panel implementation)
and Cohort 2 (the year after BioFire® ME Panel implementation).
Length of hospital stay, duration of antimicrobials, and BioFire® ME
Panel result were gathered and analyzed.
Results. Average length of stay for both cohorts was about four
hospital days. Approximately three-fourths of all patients received
antibiotic/antiviral treatment with an average of three days duration.
No significant differences were observed between groups. The mean
(median) duration of antimicrobials in the year prior to and after
the BioFire® ME Panel implementation was 3.6 (3) and 3.1 (2) days,
respectively (p = 0.835). The mean (median) length of stay in the year
prior to and after the BioFire® ME Panel implementation was 5.8 (4)
and 5.4 (4) days, respectively (p = 0.941). Among the patients admitted
after the implementation of the BioFire® ME Panel, 4.3 % (n =
2) had a positive bacterial result, 38.3% (n = 18) had a positive viral
result, and 57.4% (n = 27) had a negative result. Of the 27 negative
results, 77.8% (n = 21) were treated with antimicrobial medication.
Conclusions. This study suggested there is no difference between
length of stay or antimicrobial duration in presumed meningitis cases
assessed with traditional methods as compared to the BioFire® ME
Panel. Kans J Med 2019;12(1):1-3.